Core Insights - The article highlights the potential of antiviral therapy targeting Epstein-Barr virus in treating Long-COVID symptoms, particularly fatigue [1][6] - Virios Therapeutics is focused on developing novel antiviral therapies for chronic diseases linked to viral-triggered immune responses, including Long-COVID and fibromyalgia [2][5] Company Overview - Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company aiming to advance antiviral therapies for diseases like fibromyalgia and Long-COVID [2] - The company’s lead candidates are fixed-dose combinations of antiviral compounds and celecoxib, designed to suppress herpesvirus replication [2] Clinical Studies - The Bateman Horne Center has completed enrollment for a proof of concept study evaluating the combination of valacyclovir and celecoxib (IMC-2) for Long-COVID symptoms, with top-line results expected in October 2024 [3][4] - Previous studies indicated that the valacyclovir/celecoxib combination improved various symptoms associated with Long-COVID compared to untreated controls [4] Market Need - An estimated 17.6% of the U.S. population, nearly 45 million adults, have experienced Long-COVID since the pandemic began, highlighting a significant unmet medical need for effective treatments [5] - Currently, there are no FDA-approved treatments for Long-COVID symptoms, emphasizing the urgency for new therapeutic options [5]
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center